Findings from a new study by Duke researchers are shifting the way one of the deadliest forms of lung cancer is understood and offering fresh insights that could revolutionize treatment approaches.

Cabozantinib, a tyrosine kinase inhibitor (TKI), was recently approved for patients with previously treated pancreatic NETs.

A new study reveals that small cell lung cancer (SCLC) likely begins in basal stem-like cells rather than in neuroendocrine cells ...

Morgan Stanley raised the firm’s price target on Exelixis (EXEL) to $50 from $46 and keeps an Overweight rating on the shares ...

A doctor at an Overland Park hospital made history performing the area's first non-invasive liver tumor treatment.

A new study reveals that small cell lung cancer (SCLC) likely begins in basal stem-like cells rather than in neuroendocrine cells, marking a major shift in the understanding of this aggressive disease ...

Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs) Preliminary clinical ...

Younger age at diagnosis, prior primary hyperparathyroidism, non-missense pathogenic variants, and female sex increase the ...

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will unveil ...

NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that the company’s abstract featuring first clinical data from ...

On June 3, 2025, the FDA granted Fast Track designation to CHM-CDH17, a third-generation CAR-T therapy targeting CDH17 for ...

Appendix cancer, once considered rare, is increasingly affecting younger adults, particularly those born since the 1970s.